| Identification | Back Directory | [Name]
DCPIB | [CAS]
82749-70-0 | [Synonyms]
DCPIB
4-(2-BUTYL-6,7-DICHLORO-2-CYCLOPENTYLINDAN-1-ON-5-YL)OXYBUTYRIC ACID
4-[(2-BUTYL-6,7-DICHLORO-2-CYCLOPENTYL-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)OXY]BUTANOIC ACID
Butanoic acid, 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C22H28Cl2O4 | [MDL Number]
MFCD07783995 | [MOL File]
82749-70-0.mol | [Molecular Weight]
427.36 |
| Chemical Properties | Back Directory | [Boiling point ]
593.8±50.0 °C(Predicted) | [density ]
1.262±0.06 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
insoluble in H2O; ≥49.8 mg/mL in EtOH; ≥50.8 mg/mL in DMSO | [form ]
solid | [pka]
4.53±0.10(Predicted) | [color ]
White | [InChI]
1S/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26) | [InChIKey]
KHKGTPJPBOQECW-UHFFFAOYSA-N | [SMILES]
CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C3CCCC3 |
| Hazard Information | Back Directory | [Uses]
DCPIB is a potent, selective blocker of the volume-sensitive anion channel (VSAC) in rat pancreatic β-cells. | [Definition]
ChEBI: 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]butanoic acid is a member of indanones. | [Biological Activity]
Potent, selective blocker of the volume-sensitive anion channel (VSAC) in rat pancreatic β -cells (IC 50 ~ 2 μ M) and I Cl,swell in various cardiovascular tissues (IC 50 = 4.1 μ M in CPAE cells); blockade is voltage-independent. Displays minimal inhibition of other Cl - and K + currents (< 10% inhibition at 10 μ M). Inhibits glucose-stimulated insulin secretion in intact β -cells via VSAC inhibition and indirect K ATP channel activation. Reverses cell swelling-induced action potential duration shortening in atrial myocytes and inhibits astroglial swelling in vitro . | [in vivo]
LDN-212854 (intracerebroventricular infusion, 1 mM, 10 μL) suppresses microglial activation and ameliorates neuronal damage in rMCAO rats[3].
| Animal Model: | Reversible middle cerebral artery occlusion (rMCAO) model[3] | | Dosage: | 1 mM, 10 μL | | Administration: | Administered manually for 20s by intracerebroventricular infusion | | Result: | Diminished Pyramidal neurons injury induced by rMCAO in the CA1 region. |
| [storage]
Store at +4°C |
|
|